Phathom Pharmaceuticals (PHAT) Shares Outstanding (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Shares Outstanding (Entity) of $80.9 million for Q2 2026, up 15.4% year-over-year from $70.1 million in Q2 2025, and up 1.84% quarter-over-quarter from $79.4 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Shares Outstanding (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Shares Outstanding (Entity) for 9 consecutive years, with $80.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 15.4% year-over-year to $80.9 million; the TTM figure through Jun 2026 stood at $80.9 million (up 15.4% YoY), while the FY2025 annual figure was $71.4 million, up 4.23% from the prior year.
- Shares Outstanding (Entity) improved to $80.9 million in Q2 2026 per PHAT's latest filing, from $79.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $80.9 million in Q2 2026 and bottomed at $39.1 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $59.6 million across 5 years, with a median of $58.6 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) surged 44.96% — and 2024, when it advanced 3.46%.
- Phathom Pharmaceuticals' Shares Outstanding (Entity) stood at $41.7 million in 2022, then soared by 38.94% to $58.0 million in 2023, then grew by 18.2% to $68.5 million in 2024, then grew by 4.23% to $71.4 million in 2025, then gained by 13.28% to $80.9 million in 2026.
- Business Quant data shows PHAT's Shares Outstanding (Entity) at $80.9 million in Q2 2026, $79.4 million in Q1 2026, and $71.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 83.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.75 Mn |
| Mar 31, 2026 | 82.05 Mn |
| Dec 31, 2025 | 72.92 Mn |
| Sep 30, 2025 | 73.40 Mn |
| Jun 30, 2025 | 72.47 Mn |
| Mar 31, 2025 | 71.97 Mn |
| Dec 31, 2024 | 63.18 Mn |
| Sep 30, 2024 | 64.63 Mn |
| Jun 30, 2024 | 58.56 Mn |
| Mar 31, 2024 | 58.37 Mn |
| Dec 31, 2023 | 51.29 Mn |
| Sep 30, 2023 | 56.78 Mn |
| Jun 30, 2023 | 48.50 Mn |
| Mar 31, 2023 | 42.35 Mn |
| Dec 31, 2022 | 39.12 Mn |
| Sep 30, 2022 | 38.82 Mn |
| Jun 30, 2022 | 38.27 Mn |
| Mar 31, 2022 | 38.04 Mn |
| Dec 31, 2021 | 37.00 Mn |
| Sep 30, 2021 | 37.30 Mn |